Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06305910 · ClinicalTrials.gov registry record · Phase 1
CD200AR-L and Allogeneic Tumor Lysate Vaccine Immunotherapy for Recurrent HGG and Newly Diagnosed DMG/DIPG in Children and Young Adults
A Phase 1 study of Diffuse Midline Glioma, H3 K27M-Mutant and Recurrent High Grade Glioma, sponsored by OX2 Therapeutics.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 24
- Enrollment target
- 1
- Study location
NCT06305910 is a Phase 1 study of Diffuse Midline Glioma, H3 K27M-Mutant and Recurrent High Grade Glioma that is actively recruiting participants, run by OX2 Therapeutics. The registered enrollment target is 24 participants, below the 231-participant average among 11 other Diffuse Midline Glioma, H3 K27M-Mutant trials with a reported enrollment target (90% lower). The trial reports 1 study location across 1 state.
The verdict
NCT06305910, a Phase 1 study of Diffuse Midline Glioma, H3 K27M-Mutant and Recurrent High Grade Glioma, is actively recruiting participants, sponsored by OX2 Therapeutics.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 24 participants
- Enrollment target
- 1
- Study location
Study Summary
This is a single center Phase I study of a new adjuvant CD200 activation receptor ligand, CD200AR-L, in combination with imiquimod and GBM6-AD vaccine to treat malignant glioma in children and young adults. The primary objective of this study is to determine the maximum tolerated dose (MTD) of CD200AR-L when given with a fixed dose of GBM6-AD vaccine, imiquimod, and a single dose of radiation for patients with recurrent High Grade Glioma (HGG) or following standard of care therapy radiation therapy for newly diagnosed Newly Diagnosed Diffuse Midline Glioma/Diffuse Intrinsic Pontine Glioma (DIPG/DMG).
Conditions Studied
Interventions
- DRUG Treatment with CD200AR-L
Study Locations (1)
Minnesota
- Children's Minnesota - Minneapolis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 24 participants |
| Start Date | 2024-03-15 |
| Est. Completion | 2027-01-15 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06305910
The ClinicalTrials.gov registry entry for NCT06305910 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 24 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 231-participant average among 11 other Diffuse Midline Glioma, H3 K27M-Mutant trials with a reported enrollment target (90% lower). The listed sponsor is OX2 Therapeutics, which has 1 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Diffuse Midline Glioma, H3 K27M-Mutant appearing as the primary indexed condition, and to 1 intervention - of which Treatment with CD200AR-L is the first listed.
NCT06305910 reports 1 study location spanning 1 distinct geographic area - top geographies include Minnesota.
Frequently Asked Questions
What is clinical trial NCT06305910 about?
NCT06305910 is a clinical study titled "CD200AR-L and Allogeneic Tumor Lysate Vaccine Immunotherapy for Recurrent HGG and Newly Diagnosed DMG/DIPG in Children and Young Adults". This is a single center Phase I study of a new adjuvant CD200 activation receptor ligand, CD200AR-L, in combination with imiquimod and GBM6-AD vaccine to treat malignant glioma in children and young adults. The primary objective of this study is to determine the maximum tolerated dose (MTD) of CD20...
What is the current status of trial NCT06305910?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 24 participants. The study started on 2024-03-15. Estimated completion is 2027-01-15.
What conditions does trial NCT06305910 study?
This clinical trial studies the following conditions: Diffuse Midline Glioma, H3 K27M-Mutant, Recurrent High Grade Glioma.
What interventions are being tested in trial NCT06305910?
The interventions under investigation include: Treatment with CD200AR-L (DRUG).
Who is sponsoring clinical trial NCT06305910?
This trial is sponsored by OX2 Therapeutics, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06305910 being conducted?
This trial has 1 study location across Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Diffuse Midline Glioma, H3 K27M-Mutant
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Genetically Modified Cells (KIND T Cells) for the Treatment of HLA-A*0201-Positive Patients With H3.3K27M-Mutated Glioma
RECRUITING · Phase 1
-
FUS Etoposide for DMG
RECRUITING · Phase 1
-
Atovaquone Combined With Radiation in Children With Malignant Brain Tumors
RECRUITING · Phase 1
-
Loc3CAR: Locoregional Delivery of B7-H3-CAR T Cells for Pediatric Patients With Primary CNS Tumors
RECRUITING · Phase 1
-
rHSC-DIPGVax Plus Checkpoint Blockade for the Treatment of Newly Diagnosed DIPG and DMG
RECRUITING · Phase 1
-
Study of Ribociclib and Everolimus in HGG and DIPG or Ribociclib and Temozolomide in DHG, H3G34-mutant
RECRUITING · Phase 2
Explore more on PlainTrial
Diffuse Midline Glioma, H3 K27M-Mutant
All registered trials for this condition
Recurrent High Grade Glioma
All registered trials for this condition
Minnesota
All trials with a study site in Minnesota
Recruiting now
Find trials open to new participants near you
Rankings
Top sponsors, conditions, and phases
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.